EU regulator backs GSK’s rubella virus vaccine for use in adults aged 50-59 years
The European Union’s health regulator has recommended expanding the use of GSK’s respiratory syncytial virus (RSV) vaccine to adults aged 50-59 years. The vaccine, called Arexvy, was approved by the US Food and Drug Administration in June.
ПОПУЛЯРНЫЕ ПОСТЫ
UK sets new climate target for 2035
Ноябрь 13, 2024
Children go back to school after Valencia floods
Ноябрь 13, 2024
Researchers document huge decline in African elephants
Ноябрь 13, 2024
Mission: Impossible 8 title revealed
Ноябрь 13, 2024
ПОДПИСЫВАЙТЕСЬ НА НАС
ПРЯМАЯ ТРАНСЛЯЦИЯ